Using modified immune cells to treat lung cancer
Official title: Flt3l gene-modified cDC1 in situ vaccination in NSCLC: mechanisms and therapeutic application
Funded at VA Greater Los Angeles Healthcare System · NIH-10863820 · Data updated 2026-11-12
This study is exploring a new way to boost the immune system's fight against non-small cell lung cancer by using specially modified cells to help activate T cells right in the tumor, and it could offer new hope for patients looking for better treatment options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Greater Los Angeles Healthcare System NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| NIH project number | 5IK2BX006194-02 |
| Project ID | NIH-10863820 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with non-small cell lung cancer who are seeking new treatment options.
✕Less likely to help
Patients with other types of lung cancer or those who are not eligible for immunotherapy may not benefit from this research.
What this research studies
This research focuses on enhancing the immune response against non-small cell lung cancer (NSCLC) by modifying dendritic cells to improve their ability to stimulate T cells. The approach involves using gene-modified cells to create a localized vaccination effect within the tumor environment. Patients may benefit from this innovative immunotherapy that aims to activate their immune system to better fight cancer. The research is being conducted by a team of experts in lung cancer and immunology, ensuring a robust methodology and support.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for lung cancer, potentially improving survival rates and quality of life for patients.
How similar studies have gone: Previous research has shown promising results with similar immunotherapy approaches, indicating potential for success in this area.
Where this research is happening
-
VA Greater Los Angeles Healthcare System
Los Angeles, United States Active
Researchers
- Principal investigator: Salehi-Rad, Ramin — VA Greater Los Angeles Healthcare System
- Study coordinator: Salehi-Rad, Ramin
Related research
Other NIH-funded projects on the same topics.
-
Gene-modified immune-cell vaccine for non-small-cell lung cancer
This project develops a gene-modified dendritic-cell vaccine to boost the immune system against non-small-cell lung cancer.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
7-marker protein test to predict NSCLC response to anti-PD-1 therapy
A Johns Hopkins team is testing a 7-marker protein test to help predict which advanced NSCLC patients will respond to anti-PD-1 therapy.
-
Respiratory pathogen–specific T cell signatures after vaccination, infection, and treatment
A research effort to map how immune T cells respond to respiratory infections and vaccines, with potential to guide better vaccines and treatments for conditions like covid-19 and pertussis.
-
Malaria vaccine and infection: how the body’s early and later immune responses relate to protection
Researchers are studying how people’s immune systems respond to the malaria pre-erythrocytic stage, whether after vaccination or infection, to identify which responses are linked to protection.
-
Spatially responsive mass vaccination for urban rabies
A new plan uses data and maps to place vaccination sites where they’re most needed in cities, aiming to boost rabies vaccination for both people and dogs.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.